BASKET LATE: Basel Stent Cost-effectiveness Trial - Late Thrombotic Events Trial

      -Higher Risk of Late Death/MI Among Patients Treated with DES vs Bare Metal Stents by Dr. Matthias E. Pfisterer (ACC 2006)

Bern-Rotterdam Registry

      -Early and Late Coronary Stent Thrombosis of Sirolimus-eluting and Paclitaxel-eluting Stents in Routine Clinical Practice: Data from a Large Two-institutional Cohort Study by Dr. Joost Daemen, et al. (2007)

Clopidogrel Loading Dose

      -Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring Decrease Early Stent Thrombosis by Dr. Laurent Bonello

DEScover Registry: An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting

      -One-Year Clinical Results by Dr. David O. Williams and Dr. J. Dawn Abbott (TCT 2006)

Drug-Eluting Stents (DES) Thrombosis

      -DES Thrombosis: Future Trials of DES Thrombosis (TCT 2006)

      -Impact of Platelet Reactivity Following Clopidogrel Administration on Drug Eluting Stent Thrombosis

      -Late Thrombosis in DES: Meta-Analysis of All Published Case Reports by Dr. Ramin Artang, et al.

      -Meta Analysis of Risk of Thrombosis Among Drug Eluting Stent vs Bare Metal Stent by Dr. Bavry and Dr. Bhatt, et al. (2006)

HORIZONS-AMI: Harmonizing Outcomes with Revascularization and Stents in AMI

      -Stent Thrombosis Following Primary PCI in STEMI: Predictors, Clinical Impact and Preventive Strategies from the Horizons AMI Trial by Dr. George D. Dangas (TCT 2009)

PREMIER Registry

      -Mortality Data from the BASKET LATE Trial and PREMIER Registry

Restenosis

      -In-Stent Restenosis and Late Stent Thrombosis by Dr. Roxana Mehran

STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients

      -Stent Thrombosis as an Increasing Cause of STEMI by Dr. Bruce Brodie (TCT 2009)

(Return to Contents)

Slides from the FDA Circulatory System Devices Panel: Open Public Hearing (December 7 , 2006)

ARTS II: Arterial Revascularization Therapies Study Part II

      -Adjudication of Events for FDA Panel | (pdf) by Dr. Gerrit-Anne van Es

CYPHER® Sirolimus-Eluting Stent

      -"Real-World" Use of the CYPHER® Sirolimus-Eluting Stent: Data from Randomized Controlled Trials and Registries | (pdf) by Dr. Sidney A. Cohen

Drug-Eluting Stents - The Vascular Pathology

      -Delayed Healing and Late Thrombotic Risk | (pdf) by Dr. Renu Virmani, et al. (2006)

Drug-Eluting Stent Safety

      -And Efficacy: With Regulatory Recommendations | (pdf) by Dr. Gregg W. Stone

      -Stent Thrombosis | (pdf) by Dr. Campbell Rogers

Drug Eluting Stent Thrombosis

      -Incidence and Predictors of Drug Eluting Stent Thrombosis during and Following Discontinuation of Thienopyrdine Treatment | (pdf) by Dr. Antonio Colombo

Drug-Eluting Stent vs. Bare Metal Stent

      -Long-term outcome of DES vs BMS implanted in Sweden 2003 – 2004 | (pdf) by Dr. Bo Lagerqvist and Dr. Lars Wallentin, et al. (2006)

FDA

      -FDA Summary | (pdf) by Dr. Takahiro Uchida, et al.

The J-Cypher Registry Update

      -Preliminary One-Year Outcome After Sirolimus-eluting Stent Implantation | (pdf) by Dr. Takeshi Kirmura, et al.

Late Coronary Stent Thrombosis of DES in Routine Clinical Practice

      -Data from a Large Two-Institutional Cohort Study by Dr. Joost Daemen

Late Stent Thrombosis After DES

      -Role of Platelet Function Testing | (pdf) by Dr. Alan D. Michelson

Meta-Analyses of Randomized Trials of Sirolius-Eluting Stents vs. Paclitaxel-Eluting Stents of Bare Metal Stents

      -An Independent, Individual Patient Data Based Study | (pdf) by Dr. Adnan Kastrati and Dr. Albert Schömig

Sirolimus-eluting Stents in Comparison with Bare Metal Stents

      -A Pooled Safety Analysis of the RAVEL, SIRIUS, E-SIRIUS, and C-SIRIUS Trials | (pdf) by Dr. Patrick W. Serruys

Stent Thrombosis

      -The Implications of Broader DES Use | (pdf) by Dr. Robert P. Fiorentino

      -Stent Thrombosis Impact on Outcomes of Death and MI after Drug-Eluting Stenting: Importance of Standard Definitions and Analytical Methods | (pdf) by Dr. Donald E. Cutlip

TAXUS Drug-eluting Stent

      -On-label Use of the TAXUS Drug-eluting Stent System | (pdf) by Dr. Donald S. Baim

      -Real-world use of the TAXUS Drug-eluting Stent System | (pdf) by Dr. Donald S. Baim

Thoraxcenter

      -Thoraxcenter Real World Experience | (pdf) by Dr. Patrick Serruys

(Return to Contents)

Slides from the FDA Circulatory System Devices Panel: Open Public Hearing Speakers (December 8 , 2006)

ACC Testimony

      -Circulatory Systems Devices Panel of the Medical Devices Advisory Committee, FDA | (pdf) by Dr. James T. Dove

Clinical Selection

      -Relative Merits and Clinical Selection of CABG, Bare Metal Stents, and Drug Euting Stents in Practice and in Evolution | (pdf) by Dr. Peter K. Smith

Clopidogrel Therapy

      -What is the Right Dose, Timing, and Duration of Clopidogrel Therapy when Used with Drug Eluting Stents? | (pdf) by Dr. Robert S. Hillman

Drug-Eluting Stents (DES)

      -Abbott Vascular Drug Eluting Stent Program | (pdf) by Dr. Krishna Sudhir

      -Balancing Risks and Benefits | (pdf) by Dr. Sanjay Kaul and Dr. George A. Diamond

      -Balancing Risks and Benefits | (pdf) by Dr. Jeffrey Moses

      -DES in Thrombosed Coronary Lesions | (pdf) by Dr. Jim Gustafson

      -DES Overview | (pdf) by Dr. Mark A. Turco

      -FDA Panel on DES by Dr. Alexandre Abizaid

      -Longitudinal Outcomes Following Drug Eluting Stent Implantation | (pdf) by Dr. David Magid, Dr. Ralph Brindis, and Dr. Alan S. Go

      -Prairie "Real World" Drug Eluting Stent Database: Springfield, Illinois by Dr. Gregory Mishkel and Anna Moore, MPH

Drug-Eluting vs. Bare Metal Stents

      -Results from a Practice-Based Registry | (pdf) by Dr. Eric L. Eisenstein, et al.

      -Findings from the NHLBI-Dynamic and the DEScover Registries | (pdf) by Dr. David O. Williams

Drug-Eluting Stent (DES) Thrombosis

      -Late Stent Thrombosis After DES: Role of Platelet Function Testing | (pdf) by Dr. Alan D. Michelson

      -DES Thrombosis Results from Contemporary Registries | (pdf) by Dr. Ron Waksman

Impact of DES in STEMI

      -The Minneapolis Heart Institute Level 1 MI Program | (pdf) by Dr. Tim Henry

The MATRIX Trial: Long-Term Safety of DES in Off-Label Use

      -A Prospective "All Comers" Single Arm Study in Complex Patients by Dr. Roxana Mehran

Medtronic Vascular

      -Endeavor Safety Analysis | (pdf) by Dr. Rick Kuntz

Protecting Patients

      -Protecting Patients Through Informed Consent and Appropriate Therapy | (pdf) by Dr. Frederick Grover

Safety

      -Planned Combined Safety Analysis for Stents Utilizing Biolimus A9® and Biodegradable Polymer | (pdf) by Dr. Laura Mauri

SCAI View

      -Public Statement to The FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee by Dr. Gregory J. Dehmer

Summary Recommendations to FDA

      -Society of Thoracic Surgeons' Perspective | (pdf) by Dr. T. Bruce Ferguson Jr.

(Return to Contents)

Bare Metal Stents Instead of Drug-Eluting Stent

      -When Changing One Word Can Save a Life: Bare Instead of Eluting by Ryszard Rokicki

One Man's Personal Story

      -Rick Dulin Describes His Personal Experience With a Drug-Eluting Stent and Expresses His Wishes to the Panel by Rick Dulin

(Return to Contents)

Who Are We?    Slide Downloading Policy   Financial Disclosure    We Do Not Promote Off Label Product Use    Copyright    Source of Slides    Editorial Policy    Links Policy    Privacy Policy   Access    CME Programs